TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12362542
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical probability assessment and D-dimer measurement
Study: 8575688
Drug: High-dose pure
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pure follicle-stimulating hormone (pFSH) (Metrodin)
Study: 2406327
Drug: Low-dose allergoid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose allergoid (maximal dose: 2000 PNU)
Study: 2406327
Drug: High-dose allergoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose allergoid (maximal dose: 10,000 PNU)
Study: 30883839
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets 3.5 mg/kg and 5.25 mg/kg
Study: 26102724
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg/Hydrochlorothiazide 12.5 mg (NH)
Study: 26102724
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/Hydrochlorothiazide 12.5 mg (IH)
Study: 23916740
Drug: Extrafin BDP/F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafin BDP/F 400/24 μg
Study: 23916740
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose FP/S 1000/100 μg
Study: 23916740
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose FP/S 500/100 μg
Study: 16763490
Drug: efavirenz-containing highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz-containing highly active antiretroviral therapy (zidovudine + lamivudine + efavirenz)
Study: 16763490
Drug: efavirenz-containing highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz-containing highly active antiretroviral therapy
Study: 9786640
Drug: Mandibular implant-retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mandibular implant-retained overdentures (mainly implant-borne on a transmandibular implant)
Study: 9786640
Drug: Mucosa-borne overdentures
Normalized name: Sus scrofa oral mucosa preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosa-borne overdentures on two cylindric permucosal IMZ implants
Study: 9786640
Drug: Mainly implant-borne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainly implant-borne (TMI) and mucosa-implant-borne (IMZ) implant systems
Study: 7888419
Drug: Fluoxetine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (120 mg/week, administered biweekly)
Study: 28856601
Drug: Cr-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr-enriched yeast (200 μg of elementary Cr in the morning and 100 μg in the evening)
Study: 27004289
Drug: Laser-collar-treated implants
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-collar-treated implants
Study: 27004289
Drug: Nanosurface-treated implants
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanosurface-treated implants
Study: 12560428
Drug: Systemic adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic adjuvant chemotherapy (in all treatment arms)
Study: 10472226
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with hyperbaric lidocaine 50 mg ml‐1 (85‐100 mg)
Study: 7593777
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg daily for 12 weeks) after initial treatment
Study: 1948277
Drug: Mefloquine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 500 mg fortnightly
Study: 1948277
Drug: Chloroquine 300
Normalized name: chloroquine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 300 mg base weekly plus Fansidar (1000 mg sulfadoxine and 50 mg pyrimethamine) fortnightly
Study: 1948277
Drug: Chloroquine 300
Normalized name: chloroquine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 300 mg base weekly
Study: 348251
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily for six weeks (subsequent treatment for non-healing controls)
Study: 31512160
Drug: Chest physiotherapy
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest physiotherapy (CP) applied twice a day for 4 days post-surgery
Study: 26255508
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of relaxing needling technique combined with wheat-grain moxibustion
Study: 11204933
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg) and Lacidipine (4 mg) in hypertensive patients
Study: 9449682
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (50 pmol/kg.h)
Study: 2842680
Drug: 3.2 g
Normalized name: OATMEAL 2.3 g in 113.2 g TOPICAL CREAM [EczeNil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 g of eicosapentaenoic acid per day (treatment group)
Study: 2842680
Drug: Conventional antiplatelet
Normalized name: magaldrate and antiflatulents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiplatelet regimen (325 mg of aspirin and 225 mg of dipyridamole per day; control group)
Study: 29166538
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with 100 μg mL‐1 methylene blue and low power laser (InGaAIP, 660 nm; 100 mW; 40 s)
Study: 25893359
Drug: Epidural perineural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural perineural injection of autologous conditioned serum (ACS) 2.5 to 3 mL
Study: 25893359
Drug: Methylprednisone (MPS)
Normalized name: Methylprednisolone
DrugBank: Methylprednisone (DB12952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisone (MPS) 2.5 to 3 mL
Study: 17177582
Drug: Tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1 mg/kg every 6 hours, increasing to 1.5 mg/kg if necessary)
Study: 9571254
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy plus intravenous cytarabine
Study: 9571254
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy plus intrathecal cytarabine
Study: 8169802
Drug: Dispersion formulation
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersion formulation under fasting conditions
Study: 8169802
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation under fasting conditions
Study: 8169802
Drug: Capsule formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation with food
Study: 8169802
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of capsule formulation with food to without food
Study: 27175448
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea supplements
Study: 17563128
Drug: Escitalopram 10-20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10-20 mg/day (fixed at 10 mg/day for the first 4 weeks)
Study: 15728164
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + MPA (0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate)
Study: 15728164
Drug: CEE (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (0.625 mg/d of conjugated equine estrogen)
Study: 12496752
Drug: Flumazenil (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.005 mg/kg)
Study: 31786934
Drug: Midazolam (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.025 mg/kg)
Study: 9440475
Drug: Pro‐Z (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro‐Z (200 mg bovine prostate powder supplemented with 20 mg zinc)
Study: 21138455
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g mesalazine once daily (OD)
Study: 21138455
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g mesalazine once daily (OD)
Study: 21138455
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g mesalazine three times daily (t.d.s.)
Study: 16998452
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (450 mg of a‐tocopherol for 8 weeks)
Study: 16998452
Drug: Placebo (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (450 mg of lactose for 8 weeks)
Study: 1343896
Drug: Yearly drug
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yearly drug therapy for S. haematobium infection
Study: 1343896
Drug: Repeat therapy
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat therapy in years 2 and 3
Study: 1343896
Drug: Annual therapy
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual therapy re-instituted in 1989 and 1990
Study: 3977334
Drug: 1% minoxidil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% minoxidil solution
Study: 3977334
Drug: 1% and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% and 5% minoxidil solutions
Study: 31976867
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with clopidogrel
Study: 31976867
Drug: Morphine without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine without clopidogrel
Study: 20945945
Drug: LTRA (pranlukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTRA (pranlukast 7 mg/kg bodyweight/day)
Study: 15985095
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment (Control)
Study: 8692118
Drug: s.c. rIL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. rIL-2 and rIFN-alpha 2 in combination
Study: 1526044
Drug: Nasal autoinflation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal autoinflation of a toy balloon 3 times daily for 3 weeks
Study: 6514657
Drug: Modified fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified fasting (33-50 g protein/day, 1-10 g fat/day, 25-45 g carbohydrates/day, providing 240 to 450 kcal/day)
Study: 26817454
Drug: Active intralymphatic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active intralymphatic immunotherapy (ILIT) with 1000 SQ-U birch- or grass-pollen
Study: 26817454
Drug: Active intralymphatic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active intralymphatic immunotherapy (ILIT)
Study: 25511777
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with 1000 μg/ml toluidine blue O (TBO) and red LED irradiation applied six times (twice per day) over four days.
Study: 25511777
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with 500 μg/ml TBO and LED irradiation for 20 s.
Study: 22994458
Drug: Comprehensive migraine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive migraine intervention (including education, sumatriptan 100 mg, naproxen 500 mg, and expedited headache clinic appointment)
Study: 15782422
Drug: Antimicrobial lozenge
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial lozenge
Study: 1415366
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly subcutaneous administration of recombinant human erythropoietin (rHuEPO)
Study: 1415366
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly subcutaneous administration of recombinant human erythropoietin (rHuEPO)
Study: 22828718
Drug: HIV-1 RNA
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 RNA >400 copies/mL
Study: 22828718
Drug: Protease-inhibitor (PI)-based
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease-inhibitor (PI)-based regimen
Study: 18050577
Drug: EDTA gel
DrugBank: Edetate sodium (DB13404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA gel combined with 5.25% sodium hypochlorite (Group 3)
Study: 18050577
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gel (Group 4)
Study: 18050577
Drug: 5.25% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.25% sodium hypochlorite combined with Glyde File Prep gel (Group 5)
Study: 16085507
Drug: 2-mg Nicorette
Normalized name: nicotine 2 MG [Nicorette]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg Nicorette gum
Study: 11966664
Drug: Intravenous M6G
Normalized name: M6G
DrugBank: Morphine glucuronide (DB06409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous M6G 2 mg
Study: 11966664
Drug: Subcutaneous M6G
Normalized name: M6G
DrugBank: Morphine glucuronide (DB06409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous M6G 2 mg
Study: 11966664
Drug: Nebulized M6G
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized M6G 4 mg
Study: 11966664
Drug: Oral M6G
Normalized name: M6G
DrugBank: Morphine glucuronide (DB06409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral M6G 20 mg
Study: 11966664
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and subcutaneous M6G
Study: 10189144
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no calcium antagonist)
Study: 7478029
Drug: Heparin/nitroglycerin infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin/nitroglycerin infused in the same site
Study: 7478029
Drug: Heparin/nitroglycerin infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin/nitroglycerin infused in separate sites
Study: 29982371
Drug: Functional appliance
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional appliance treatment for 12 months
Study: 29982371
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (age- and gender-matched children without immediate orthodontic treatment need)
Study: 27605591
Drug: Accu-Chek® FlexLink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accu-Chek® FlexLink infusion set (FL)
Study: 25322972
Drug: Music Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Medicine (MM)
Study: 21550483
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus clavulanic acid (3 g per day for 8-15 days)
Study: 15163472
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (30.5 g fiber, 4.11 g soluble fiber)
Study: 15163472
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (10.4 g fiber, 1.97 g soluble fiber)
Study: 15321225
Drug: Epidural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural diamorphine 2.5 mg in 10 ml normal saline following spinal anaesthesia
Study: 15321225
Drug: Epidural diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural diamorphine 2.5 mg in 10 ml normal saline following conventional epidural anaesthesia
Study: 8165073
Drug: Nitrofurantoin prophylaxis
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin prophylaxis (once-daily dose)
Study: 2832173
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg day-1 for 5 days
Study: 2832173
Drug: Frusemide added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide added to enalapril therapy
Study: 20860641
Drug: Acute secondhand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute secondhand smoke exposure (1 hour, mean fine particulate matter < 2.5 μm level = 315 ± 116 μg/m(3))
Study: 14514236
Drug: Dental prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental prophylaxis plus placebo capsule
Study: 14514236
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus placebo capsule
Study: 14514236
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus metronidazole capsule (250 mg t.i.d. for one week)
Study: 8864710
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) 4 g/day for at least a week
Study: 1497054
Drug: Danazol 400
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 400 mg/day for 4 months (n = 22)
Study: 6342168
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (0.25 mg/kg)
Study: 6342168
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (0.5 mg/kg)
Study: 6342168
Drug: Intravenous practolol
Normalized name: practolol
DrugBank: Practolol (DB01297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous practolol (0.4 mg/kg)
Study: 27227930
Drug: Control supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control supplement (hypercaloric hypernitrogenous supplement)
Study: 12680331
Drug: Azithromycin aspartic-acid
Normalized name: Aspartic Acid
DrugBank: Aspartic acid (DB00128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azithromycin aspartic-acid injection (monotherapy, once-daily intravenous dosing)
Study: 10232636
Drug: Retinol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinol (60 mg as retinyl palmitate)
Study: 10232636
Drug: Beta-carotene (7.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (7.6 mg daily)
Study: 10232636
Drug: Placebo (daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily)
Study: 8912406
Drug: d-fenfluramine (FEN)
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (FEN) 15 mg, PO
Study: 8912406
Drug: d-fenfluramine (FEN)
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (FEN) 30 mg, PO
Study: 28398947
Drug: 0.15 g·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 g·kg of body mass of ammonium chloride (NH4Cl, acidosis)
Study: 28398947
Drug: 0.3 g·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g·kg of sodium bicarbonate (NaHCO3, alkalosis)
Study: 28398947
Drug: 0.15 g·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 g·kg of CaCO3 (placebo)
Study: 23791495
Drug: 5mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg of morphine sulfate intramuscularly
Study: 19083486
Drug: Medical nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical nutrition therapy (MNT) emphasizing dietary folate intake, performed 5 times during the 12 weeks of the experiment.
Study: 19083486
Drug: Medical nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical nutrition therapy (MNT) emphasizing dietary folate intake.
Study: 16545010
Drug: Enfuvirtide (ENF)
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide (ENF) + optimized background (OB) therapy
Study: 16545010
Drug: Optimized background
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized background (OB) therapy
Study: 9407172
Drug: Topical melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical melatonin (0.6 mg/cm2) applied 15 min before UV irradiation
Study: 9407172
Drug: Topical melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical melatonin (0.6 mg/cm2) applied 1, 30, or 240 min after UV irradiation
Study: 27565224
Drug: Carteolol/latanoprost concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol/latanoprost concomitant therapy (n=37)
Study: 21645443
Drug: PRFA+PEI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRFA+PEI therapy group
Study: 18422519
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg sublingually
Study: 18422519
Drug: Fentanyl 0.05
Normalized name: fentanyl 0.05 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.05 mg intravenously
Study: 18422519
Drug: Fentanyl 0.1
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.1 mg intravenously
Study: 16598319
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (600 mg/day) for one month
Study: 16598319
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg twice daily) for one month
Study: 16598319
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (600 mg/day) and Gemfibrozil (600 mg twice daily) combined for one month
Study: 12902212
Drug: Risperidone (2-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2-8 mg per day; mean dose=4.15±0.4 mg per day)
Study: 9151591
Drug: Immediate transmucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate transmucosal implants with guided tissue regeneration